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Abstract
Multiple Endocrine Neoplasia type 1 (MEN1) is a rare autosomal dominant hereditary cancer
syndrome presented mostly by tumours of the parathyroids, endocrine pancreas and anterior
pituitary, and characterised by a very high penetrance and an equal sex distribution. It occurs in
approximately one in 30,000 individuals. Two different forms, sporadic and familial, have been
described. The sporadic form presents with two of the three principal MEN1-related endocrine
tumours (parathyroid adenomas, entero-pancreatic tumours and pituitary tumours) within a single
patient, while the familial form consists of a MEN1 case with at least one first degree relative
showing one of the endocrine characterising tumours. Other endocrine and non-endocrine lesions,
such as adrenal cortical tumours, carcinoids of the bronchi, gastrointestinal tract and thymus,
lipomas, angiofibromas, collagenomas have been described. The responsible gene, MEN1, maps on
chromosome 11q13 and encodes a 610 aminoacid nuclear protein, menin, with no sequence
homology to other known human proteins. MEN1 syndrome is caused by inactivating mutations of
the MEN1 tumour suppressor gene. This gene is probably involved in the regulation of several cell
functions such as DNA replication and repair and transcriptional machinery. The combination of
clinical and genetic investigations, together with the improving of molecular genetics knowledge of
the syndrome, helps in the clinical management of patients. Treatment consists of surgery and/or
drug therapy, often in association with radiotherapy or chemotherapy. Currently, DNA testing
allows the early identification of germline mutations in asymptomatic gene carriers, to whom
routine surveillance (regular biochemical and/or radiological screenings to detect the development
of MEN1-associated tumours and lesions) is recommended.
Definition
Multiple Endocrine Neoplasia Type 1 (MEN1, OMIM
131100) is a rare inherited autosomal dominant cancer
syndrome with a very high penetrance and an equal sex
distribution that is characterised by the presence of hyper-
plasia and neoplasia in at least two different endocrine tis-
sues (parathyroid adenomas, entero-pancreatic tumours
and pituitary tumours) within a single patient. Two differ-
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ent forms, sporadic and familial, have been described. The
sporadic form presents with two of the three principal
MEN1-related endocrine tumours, while the familial form
(more frequent and with an autosomal pattern of inherit-
ance) consists of a MEN1 case with at least one first degree
relative showing one of the endocrine characterising
tumours.
Epidemiology
MEN1 is a rare disease that occurs in approximately one
in 30,000 individuals with an equal sex distribution. The
MEN1 syndrome has been described in diverse geographic
regions and ethnic groups, and no racial predilection has
been demonstrated.
Endocrine and non-endocrine manifestations of the dis-
ease in MEN1 patients most often begin in the fourth or
fifth decade. The onset of the disease is rare before age 10
years.
Clinical description, diagnostic methods, 
treatments
MEN1 syndrome is characterised by the occurrence of pri-
mary tumours involving two or more endocrine tissues
within a single patient. It encompasses tumours of the
parathyroids (95% of cases), pancreatic islets (from 30 to
80% of cases) and anterior pituitary (from 15 to 90% of
cases). Other endocrine and non-endocrine lesions, such
as adrenal cortical tumours [1,2], carcinoids of the bron-
chi [3], gastrointestinal tract [4] and thymus [5], lipomas,
angiofibromas and collagenomas [6,7] have been
described, but with a lower frequency. Combinations of
over 20 different endocrine and non-endocrine tumours
and lesions have been reported [8-12]. Thus, no simple
definition of MEN1 could cover all index cases or all fam-
ilies. By definition, MEN1 should be suspected in patients
with an endocrinopathy of two of the three principally
affected organs, or with an endocrinopathy of one of these
organs plus a first-degree relative with MEN1.
MEN1 affects all age groups with an age range of 8–81
years, and more than 95% of patients develop clinical
manifestations by the fifth decade [13-15]. Hyperparathy-
roidism is the most common and usually the first clinical
manifestation of MEN1. Gastrinoma and carcinoids rep-
resent the most frequent causes of mortality. The onset of
the MEN1-associated primary hyperparathyroidism and
the onset of MEN1-associated gastrinoma and insulinoma
anticipate the onset of the corresponding sporadic coun-
terparts of three and one decades, respectively.
Parathyroids tumours
Primary hyperparathyroidism (PHPT) is the most com-
mon clinical manifestation of MEN1, affecting more than
95% of all MEN1 patients [14]. The age of the onset (typ-
ically between 20 and 25 years of age) of MEN1-associ-
ated parathyroid tumours is about three decades earlier
than that of sporadic parathyroid adenoma; these
tumours are generally characterised by multiglandular
hyperplasia [16].
Symptoms of PHPT in MEN1 are the same as those of spo-
radic PHPT. PHPT in MEN1 manifests with hypercalcae-
mia as a result of overproduction of parathyroid hormone
(PTH) by tumoural and supernumerary parathyroid
glands. PHPT is defined as an increased serum concentra-
tion of PTH (normal range 10–60 pg/ml) [17] and an
increased serum concentration of calcium (normal range
8.5–10.5 mg/dl or 2.1–2.6 mmol/l) [17]. The common
clinical manifestations of hypercalcaemia include:
1) central nervous system – altered mental status, includ-
ing lethargy, depression, decreased alertness and confu-
sion;
2) gastrointestinal tract – anorexia, constipation, nausea
and vomiting:
3) kidneys – polyuria, nycturia, polydipsia, impaired con-
centrating ability, dehydration, hypercalciuria and
increased risk for kidney stones;
4) skeleton – increased bone resorption and increased
fracture risk, mainly in women who manifest PHPT before
35 years of age;
5) cardiovascular system – hypertension, shortened QT
interval.
Moreover, hypercalcaemia may increase the secretion of
gastrin from a gastrinoma.
At present, total parathyroidectomy is the proposed effec-
tive treatment for PHPT in symptomatic hypercalcaemic
MEN1 patients. Subtotal parathyroidectomy results in a
50% risk of recurrence within 8–12 years after the inter-
vention. Total parathyroidectomy is often followed by
autotransplantation of resected fresh or cryopreserved
normal parathyroid tissue in the forearm. To prevent late
recurrence, a total parathyroidectomy followed by a life-
long treatment with vitamin D analogues is used as an
alternative. Intraoperative rapid parathormone monitor-
ing aids both detection of extra glands and immediate
assessment of the postresection parathormone level.
Pancreatic tumours
Pancreatic tumours occur in about 30–80% of MEN1
patients and are the second most frequently expressed
clinical manifestation of MEN1. They are characterised by
multiple nodular lesions developed at an early ageOrphanet Journal of Rare Diseases 2006, 1:38 http://www.OJRD.com/content/1/1/38
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[18,19]. The majority of these tumours produce excessive
amounts of hormone (gastrin, insulin, glucagons, soma-
tostatin, neurotensin or vasoactive intestinal polypeptide
(VIP)) and are associated with distinct clinical syndromes.
These hormone-secreting tumours can be detected by bio-
chemical screening for elevated serum hormone concen-
trations. The most common functional pancreatic
tumours are gastrinomas and insulinomas. Nevertheless,
about one third of pancreatic tumours are non-functional
and clinically silent. Non-functional tumours and insuli-
nomas are located within the pancreas, while gastrinomas
are often found in the soft tissue around the pancreas and
in the duodenal submucosa, but not in the mucosa where
the gastrin-producing G cells are located. Endoscopic
ultrasonography (EUS) examination is the most sensitive
imaging procedure for the detection of small (≤10 mm)
pancreatic endocrine tumours in asymptomatic MEN1
patients; its sensitivity is higher than 75%. The use of EUS
in association with Octreoscan scintigraphy increases the
pancreatic tumoural detection rate to 90% [20]; EUS
allows precise localisation of the tumours, while Octreos-
can scintigraphy gives much more information about the
spread of the disease and detects liver metastases with a
sensitivity of 92% [21].
Gastrinomas
These gastrin-secreting tumours represent more than 50%
of all pancreatic tumours in MEN1. Approximately 40%
of MEN1 patients have gastrinoma that manifests as
Zollinger-Ellison syndrome (ZES) which usually occurs
before age 40 years (about one decade earlier than spo-
radic gastrinomas) [16]. ZES may lead to upper abdomi-
nal pain, diarrhoea, oesophageal reflux, vomiting and
acid-peptic or duodenal ulcers and, more rarely, heart-
burn and weight loss. Gastrinomas represent the major
cause of morbidity and mortality in MEN1 patients, prin-
cipally due to severe multiple peptic ulcers that may per-
forate. Biochemical diagnosis is made by demonstration
of an increased basal gastric acid secretion [22]; gastri-
noma is defined as elevated basal serum concentration of
gastrin (normal range <100 ng/l) [17].
The treatment for a non-metastatic gastrinoma is surgical
resection. The treatment for multiple and disseminate gas-
trinomas consists of therapy with a human somatostatin
analogue (octreotide), administration of proton pump
inhibitors or H2-receptor blockers to reduce gastric acid
output, chemotherapy with 5-fluoroaracil and streptozo-
tocin, and surgical excision of all resectable tumours
(however, the success rate seems very low). In fact, gastri-
nomas of MEN1 syndrome are frequently multiple and
usually include a malignant component; in about 50% of
patients gastrinomas have already metastasised before the
diagnosis and 30% of patients die [23]. Patients with liver
metastases have a poor prognosis for survival. Prognosis
does not seem negatively influenced by nodal metastases.
Pancreatic gastrinomas are more aggressive than duode-
nal gastrinomas due to their larger size and greater risk for
hepatic metastases.
Insulinomas
These insulin-secreting tumours arise in about 10% of
MEN1 patients, often in association with gastrinomas,
and have approximately one decade earlier onset than
that of sporadic insulinomas [16]. Pancreatic insulinoma
is characterised by fasting hypoglycaemia; biochemical
analysis reveals increased plasma or serum insulin con-
centration (reference values 2–20 U/ml or 14.35–143.5
pmol/l) together with high plasma or serum concentra-
tion of C-peptide (reference values 0.5–2.0 ng/ml or
0.17–0.66 nmol/l) [16]. Since medical control of symp-
toms is limited, surgery is the main treatment and is cura-
tive in some patients. Chemotherapy with streptozotocin
or octreotide is used for metastatic disease.
VIPoma
These vasoactive intestinal peptide (VIP)-secreting
tumours occur as WDHA syndrome, which is character-
ised by Watery Diarrhoea, Hypokalaemia and Achlorhy-
dria. [24]. VIPomas have been reported in a few MEN1
patients only. The diagnosis is made by documenting a
markedly increased plasma VIP concentration (reference
value <75 pg/ml) [17]. Surgical excision of VIPomas is
curative in many cases. In patients with unresectable
tumours, medical treatment with streptozotocin, octre-
otide, corticosteroids, indomethacin, metoclopramide
and lithium carbonate has proven beneficial.
Anterior pituitary tumours
The incidence of pituitary adenomas MEN1 patients var-
ies from 15 to 90%. Generally, symptoms depend on the
level of pituitary hormone produced and/or compression
effects due to size of the tumour. Mass effects include vis-
ual field defects, headaches and blurred vision. Approxi-
mately 60% of MEN1-associated pituitary tumours secrete
prolactin (prolactinomas), 25% secrete growth hormone
(GH) causing gigantism in children and acromegaly in
adults, 3% secrete adenocorticotrophin (ACTH) causing
hypercortisolism, and the others seem to be non-func-
tional. Pituitary tumours can be detected by computed
tomography (CT) scanning and nuclear magnetic reso-
nance imaging (MRI). Treatment of pituitary tumours
consists of drug therapy and/or surgery often in associa-
tion with radiotherapy of the residual unresectable
tumours.
Prolactinoma
These prolactin-secreting tumours are the most common
pituitary tumours in MEN1 and they are characterised by
the increased serum concentrations of prolactin (referenceOrphanet Journal of Rare Diseases 2006, 1:38 http://www.OJRD.com/content/1/1/38
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values: premenopausal women 0–20 ng/ml; postmeno-
pausal women 0–15 ng/ml; men 0–15 ng/ml) [17]. Prol-
actinomas induce galactorrhoea, amenorrhoea and
infertility in women, and hypogonadism, sexual dysfunc-
tion and, more rarely, gynecomastia in men. Medical
treatment consists of dopamine agonists such as cabergo-
line, bromocriptine, pergolide and quinagolide [25].
Associated endocrine tumours
Adrenal cortical tumours
The incidence of adrenal cortical tumours (involving one
or both adrenal glands) in MEN1 patients has been
reported to be approximately 20–40% [2]. The majority of
these tumours are non-functioning. However, functioning
adrenal cortical tumours are associated with elevated
serum concentrations of cortisol causing hypercortisolae-
mia and Cushing's syndrome. Although general agree-
ment does not exist, some authors recommend surgical
removal of adrenocortical tumours greater than 3 cm in
diameter because of their malignant potential.
Thyroid tumours
Thyroid tumours, consisting of adenoma, colloid goitres
and carcinomas have been reported to occur in over 25%
of MEN1 patients [13]. As the prevalence of thyroid disor-
ders in the general population is high, the occurrence of
thyroid lesions in MEN1 patients may be incidental and
not significant.
Non-endocrine associated tumours
Carcinoid tumours
These tumours are estimated to occur in about 10% of
MEN1 patients and may be located in the bronchi, the
gastrointestinal tract, the pancreas or the thymus. Thymic
carcinoids are more prevalent in males than in females
[26], while bronchial carcinoids are more prevalent in
females than in males. Carcinoids are generally silent and
most patients are asymptomatic. Rarely, thymic, bron-
chial and gastric carcinoids oversecrete ACTH, calcitonin,
GHRH, serotonine or histamine, and rarely cause carci-
noid syndrome. Carcinoids can be detected and localised
by X-ray CT examination.
Facial angiofibromas
Multiple facial angiofibromas have been observed in 88%
of MEN1 patients [6]. They are benign tumours compris-
ing blood vessels and connective tissue, and consist of
acneiform papules that do not regress.
Facial collagenomas
These multiple, skin-coloured, sometimes hypopig-
mented cutaneous nodules have been reported in >70%
of MEN1 patients [6]. They manifest in a symmetrical
arrangement on the trunk, neck and upper limbs. They are
typically asymptomatic, round-shaped and firm-elastic in
nature, and can range from few millimetres to several cen-
timetres in size.
Lipomas
Lipomas occur in 20–30% of MEN1 patients [6]. They are
generally multiple benign fatty tissue tumours that are
subcutaneous or, rarely, visceral. When surgically
removed, they usually do not recur.
Cutaneous tumours (angiofibromas, collagenomas, lipo-
mas) may help the presymptomatic diagnosis of MEN1,
before manifestations of hormone-secreting tumours
appear.
Meningiomas
They are mainly asymptomatic and in 60% of cases show
no growth.
Molecular genetics of MEN1 syndrome
The MEN1 gene
The gene locus causing MEN1 has been localised to chro-
mosome 11q13 by studies of loss of heterozigosity (LOH)
on MEN1-associated tumours and by linkage analysis in
MEN1 families [27-30]. The results of these studies agree
with Knudson's "two hits" model for tumour develop-
ment [31] and indicated that the MEN1 gene is a putative
tumour suppressor gene. The mutated MEN1 allele is a
germline mutation present in all cells at birth. The second
mutation is a somatic mutation that occurs in the predis-
posed endocrine cell and leads to loss of the remaining
wild type allele; it gives cells the survival advantage
needed for tumour development.
In 1997 the responsible gene, MEN1, was identified by
positional cloning [32]. It spans about 10 Kb and consists
of ten exons encoding a 610 amino acid nuclear protein,
named menin. Mutation analysis revealed that the MEN1
gene was frequently, but not always, mutated in MEN1
families [32]. To date, more than 400 different germline
or somatic mutations have been reported in MEN1 fami-
lies and sporadic cases from several international studies.
Mutations are distributed over the entire coding region
without showing any significant hot spot region [33-38].
Approximately 20% of mutations are nonsense muta-
tions, about 50% are frameshift insertions and deletions,
20% are missense mutations and about 7% are splice site
defects. The nonsense mutations and many of the
frameshift insertions and deletions and donor-splice site
mutations are truncating mutations predicting a loss-of-
function of menin, and therefore supporting the hypoth-
esis that MEN1 is a tumour suppressor gene. About 68%
of identified missense mutations occur on an amino acid
that is conserved among humans, mice, zebrafish and
Drosophila. More than 10% of the MEN1 mutations arise
de novo and may be transmitted to subsequent genera-Orphanet Journal of Rare Diseases 2006, 1:38 http://www.OJRD.com/content/1/1/38
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tions. Nevertheless, about 10–20% of MEN1 patients may
not harbour mutations within the coding region of the
MEN1  gene [15,33-35,39]; these individuals may have
mutations in the promoter or untranslated regions
(UTRs), which remain to be investigated. Moreover,
because all MEN1 families investigated to date have tight
linkage to 11q13, the presence of another tumour sup-
pressor gene in this region is also a possibility [40].
The MEN1 protein (menin)
MEN1 gene encodes a 610 amino acid (67 Kda) nuclear
protein that is highly conserved among humans, mice
(98%) and rats (97%), and more distantly among
zebrafish (75%) and Drosophila (47%) [41-45]. Analysis
of the menin amino acid sequence did not reveal homol-
ogy to any other known protein, sequence motif or signal
peptide, thus the putative function of menin could not be
deduced. Since the amino acid sequence and mutation
profile of menin provide a few clues to the functions of
menin, most of what is known about its role is derived
from in vitro studies. These studies revealed that menin is
located primarily in the nucleus [46] and identified at
least two independent nuclear localisation signals (NLSs)
in the C-terminus of the protein. None of the MEN1 mis-
sense mutations or in-frame deletions [3,15,33-36,47-50]
alter either of these NLSs. However, all truncating muta-
tions induce a lack of at least one of these NLSs. The
nuclear localisation of menin suggests that this protein
may have an important role in the regulation of DNA
transcription and replication, in cell cycle, or in the main-
tenance of genome integrity. Recent studies have demon-
strated that over-expression of menin in a Ras-
transformed NIH3T3 cell model reversed the transformed
phenotype [51], inducing decreased proliferation, sup-
pression of growth in soft agar and inhibition of tumour
growth in nude mice. There is increasing evidence that
menin may act in DNA repair or synthesis, but the exact
mechanism by which menin regulates DNA synthesis or
DNA repair in response to DNA damage, is currently
unknown. In the last years menin has been shown to
interact with several proteins of known functions.
The first identified partner of menin was JunD, a tran-
scriptional factor belonging to the AP1 transcription com-
plex family. Menin interacts with the N-terminus of JunD
through its N-terminus and central domains (which are
critical for this interaction). Wild type menin represses
JunD-activated transcription maybe via a histone deacety-
lase-dependent mechanism [52,53].
Menin interacts, directly, with three members of the
nuclear factor NF-kB family of transcription regulators:
NF-kB1 (p50), NF-kB2 (p52) and RelA (p65) [54]. These
proteins modulate the expression of various genes and are
involved in the oncogenesis of numerous organs. Menin
interacts with NF-kB by its central domain and represses
NF-kB-mediated transcription.
Moreover, menin interferes with the Transforming
Growth Factor beta (TGFβ) signalling pathway at the level
of Smad3. Alteration of the TGFβ signalling pathways is
important in pancreatic carcinogenesis.
Even the rodent protein Pem has been shown to bind
menin directly [55]. Pem is a homeobox-containing pro-
tein which plays a role in the regulation of transcription.
However, since Pem sequence has no known homolog in
the human genome, its direct relevance to MEN1 in
humans is still controversial. Mouse and human menin
are very similar and this could suggest the existence of a
human protein, with a function similar to that of Pem,
which binds menin and thus plays a role in the patho-
genicity of MEN1 mutations.
Although menin has been identified primarily as a nuclear
protein, recent studies have reported its interaction with
the glial fibrillary acid protein (GFAP) and with vimentin
(components of intermediate filaments (IFs)), suggesting
a putative role in glial cell oncogenesis.
Finally, menin interacts with the metastasis suppressor
Nm23H1 [56]. This interaction enables menin to act as an
atypical GTPase and to hydrolyze GTP. The binding of
menin to Nm23H1 may be relevant also to the control of
genomic stability, as Nm23H1 is associated to the centro-
some that is involved in the maintenance of chromosome
integrity. This may be supported by the fact that normal
cells from MEN1 patients present an elevated level of
chromosome alterations [57-60] and that MEN1 tumours
have more genome aberrations than equivalent tumours
from non-MEN1 patients [61].
Management
As many of the organs at highest risk of tumour develop-
ment in MEN1 syndrome such as duodenum, pancreas
and lungs (bronchial carcinoids) are not suitable for pre-
ventive ablative surgery, routine surveillance of asympto-
matic MEN1 at-risk individuals by biochemical analysis
and imaging procedures (beginning in early childhood
and continuing for life) is recommended. In fact, early
detection and treatment of the potential malignant neu-
roendocrine tumours should reduce the morbidity and
mortality of MEN1 syndrome. Such screenings can detect
the onset of the disease about ten years before symptoms
develop and thus provide an opportunity for earlier treat-
ment.
According to the International Guidelines for Diagnosis
and Therapy of the MENs syndromes [16] the minimal
surveillance program for individuals known to haveOrphanet Journal of Rare Diseases 2006, 1:38 http://www.OJRD.com/content/1/1/38
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MEN1 syndrome or to have a family-specific mutation of
the MEN1 gene should include:
1) biochemical evaluation of serum concentration of pro-
lactin from age 5;
2) biochemical screening of fasting total serum calcium
concentration (corrected for albumin) from age 8;
3) biochemical screening of fasting serum gastrin concen-
tration from age 20;
4) magnetic resonance imaging (MRI) of the head from
age 5 and every 3–5 years;
5) abdominal CT or MRI from age 20 and every 3–5 years;
It should also be considered:
1) biochemical screening of fasting serum concentration
of full-length PTH;
2) yearly chest CT;
3) yearly somatostatin receptor scintigraphy (SRS)
4) yearly Octreotide scan.
Individuals who have a 50% risk of having MEN1 syn-
drome, but whose genetic status is unknown, should
undergo the following tests:
1) biochemical evaluation of serum concentration of pro-
lactin from age 5;
2) biochemical screening of fasting total serum calcium
concentration (corrected for albumin) from age 10;
3) biochemical screening of fasting serum gastrin concen-
tration, if the individual has symptoms of ZES (reflux,
diarrhoea), from age 20;
4) biochemical screening of fasting serum concentration
of full-length PTH from age 10.
In addition, it is possible to perform prophylactic thymec-
tomy to prevent thymic carcinoids [16]; it should be con-
sidered at the time of neck surgery for PHPT, particularly
in men with MEN1 syndrome who are smokers and/or
have relatives with thymic carcinoids [62].
Genetic diagnosis/genetic counselling
MEN1 is a monogenic syndrome and, according to its
dominant pattern of inheritance, each affected patient has
the 50% of probability of transmitting the gene defect to
the progeny, independently by sex. Although uncommon,
this syndrome is important to be early recognised because
the gene mutations confer a high risk of multiple primary
tumours occurring at younger ages. Because of the grow-
ing number of preventive care options available to MEN1
patients and families, the early clinical and genetic identi-
fication of at-risk individuals is becoming increasingly
important.
Early recognition of affected and at-risk individuals is now
facilitated by DNA-testing [16], reducing the morbidity
and mortality of MEN1 and providing the opportunity to
initiate treatment at early stages. In fact, since genetic
screening was introduced in 1997, the identification of
MEN1 in at-risk individuals has become possible even in
the absence of more than one affected gland, or before the
manifestation of MEN1 typical lesions in first degree rela-
tives. Mutational analysis of the MEN1  gene is recom-
mended for patients who meet the clinical criteria for
MEN1 and for those in whom a diagnosis of MEN1 is sus-
pected. Identification of a mutation in a patient enables
testing for relatives. This allows early identification of
asymptomatic mutant gene carriers and provides an indi-
cation for them to undergo periodic biochemical and/or
radiological screening for MEN1-characteristic endocrine
tumours. Finding family members without a mutation
may lead to a decision for no further screening. Most lab-
oratories currently use direct DNA sequencing strategies of
the MEN1 gene coding region and intron-exon junctions.
This analysis requires a single blood sample, can be per-
formed at any age and does not need, in theory, to be
repeated.
When no MEN1 gene mutation in a MEN1 pedigree is
identified, the genetic confirmation can be achieved by
haplotype or linkage analysis of at least two generations of
affected members [16]. Haplotype analysis can be per-
formed using specific locus markers flanking the MEN1
region and reaches a degree of confidence when a substan-
tial number of affected members have been analysed.
Studies on MEN1 families demonstrated private familial
haplotype transmission correlated with the disease
[63,64].
Nevertheless, the lack of a genotype-phenotype correla-
tion means that neither the localisation nor manifesta-
tions of MEN1-associated tumours can be predicted. A
wide variability of tumour occurrence and clinical behav-
iour, even in patients sharing the same MEN1 mutation,
has been described, making it difficult to foresee the clin-
ical phenotype in asymptomatic mutant gene carriers.
MEN1 clinical manifestations, age of onset and natural
history, in fact, are widely variable even among members
of the same family. The absence of a genotype-phenotype
correlation might suggest a possible role of other modifierOrphanet Journal of Rare Diseases 2006, 1:38 http://www.OJRD.com/content/1/1/38
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genes and/or environmental factors. An understanding of
the function of MEN1 gene and of menin interacting pro-
teins, in the near future, may help correlation studies and
assist clinical management of patients.
Conclusion
MEN1 is a rare Mendelian cancer disease associated with
a variety of endocrine and non-endocrine tumours.
Although uncommon, early recognition of this syndrome
is important because the occurrence of multiple primary
tumours at young ages. In 1997 the discovery of the
MEN1 causative gene improved the possibility of early
identification of affected and at-risk individuals. In the
last decade, the increasing knowledge on the molecular
and clinical features of MEN1 syndrome, together with
the availability of genetic tests, greatly increased the
opportunities for intervention and have lead to reduced
morbidity and mortality. Further studies on the molecular
pathways of the MEN1 gene and related protein will help
to design novel and more individualised therapeutic
modalities, based on genetic information. In fact,
although the knowledge of the mechanisms of tumour
development in patients with MEN1 has grown tremen-
dously, much work lies ahead. The final goal is to offer
patients with MEN1 germline mutations an optimal can-
cer prevention and treatment program.
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